-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
Ambrx Biopharma Cayman, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2019 to Q1 2023.
- Ambrx Biopharma Cayman, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2023 was $77.2M.
- Ambrx Biopharma Cayman, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $928K, a 99.3% decline from 2021.
- Ambrx Biopharma Cayman, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $127M, a 33.2% increase from 2020.
- Ambrx Biopharma Cayman, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2020 was $95.7M.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)